What is Immune Technology?
Immune Technology Corp. operates as a specialized provider of high-precision biotechnology products, catering primarily to the rigorous demands of research institutions and healthcare organizations. The company's extensive portfolio includes primary antibodies, bacterial and viral antigens, tumor markers, and ELISA kits, all manufactured under strict ISO 9001:2015 quality standards. Beyond its product catalog, the firm offers bespoke services such as plasmid production, polyclonal antibody development, and protein synthesis. This dual-model approach allows Immune Technology to serve as a vital partner in the study of immunology and pathogen-related research, bridging the gap between laboratory-scale experimentation and clinical diagnostic requirements.
How much funding has Immune Technology raised?
Immune Technology has raised a total of $48K across 1 funding round:
Debt
$48K
Debt (2021): $48K with participation from PPP
Key Investors in Immune Technology
PPP
Public-Private Partnership
What's next for Immune Technology?
With the recent infusion of capital, Immune Technology is poised to scale its production infrastructure and expand its custom service offerings. The strategic focus will likely shift toward enhancing its R&D pipeline to address emerging needs in pathogen study and diagnostic marker development. As the company transitions through its current growth phase, the emphasis will remain on maintaining high-quality standards while scaling to meet the increasing global demand for reliable immunological reagents. Future initiatives may include the optimization of protein production workflows and the potential expansion of its client base into broader pharmaceutical and clinical research markets, ensuring long-term sustainability and competitive advantage in the life sciences landscape.
See full Immune Technology company page
